PCSK9 Inhibitors (Alirocumab, Evolocumab)

487

Summary

Alirocumab and evolocumab are PCSK9 inhibitors, a class of cholesterol-lowering drugs. They act by inhibiting PCSK9, a protease that binds and breaks down LDL receptors. This results in an increase in LDL receptor levels in the liver, which increases liver uptake of LDL and decreases LDL levels in the blood.  This decrease in circulating LDL is what makes these drugs useful in the treatment of hypercholesterolemia.